ARID1A-deficient Bladder Cancer is Dependent on PI3K Signaling, and can be Targeted via EZH2 and/or PI3K Pharmacologic Inhibition: Therapeutic Implications

ARID1A-mutant bladder cancer is dependent on PI3K signaling and is sensitive to EZH2 and/or PI3K inhibition. Clinical trials in molecularly selected patients should be considered. Cleavage Under Targets & Release Using Nuclease of RT112 cells in triplicate for ARID1A and H3K4me3

ARID1A突变型膀胱癌依赖磷脂酰肌醇3-激酶（PI3K）信号通路，且对zeste基因增强子同源物2（EZH2）抑制剂及/或PI3K抑制剂敏感。应考虑针对经分子标志物筛选的患者开展相关临床试验。本数据集包含对RT112细胞针对ARID1A与组蛋白H3赖氨酸4三甲基化（H3K4me3）开展的三次生物学重复的靶向切割与核酸酶释放法（Cleavage Under Targets & Release Using Nuclease）实验。